What is GHK-Cu?
GHK-Cu combines a short peptide with copper. It is discussed in topical skin care and tissue-remodeling research, which should be separated from injection claims.
Video overview · 3:18
GHK-Cu Copper Peptide: What the Research Actually Shows (Cream vs. Injection)
What the copper peptide is, what the cell and animal studies found, the one small randomized human trial (no objective benefit), why a skin cream and an injection are different questions, and its FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
GHK-Cu is a small copper-binding peptide found in skin creams, and it is also sold online as an injectable. It is marketed to reverse skin aging. The lab results are interesting, but the human evidence is thin. Here is what is actually known.
GHK is just three amino acids: glycine, histidine and lysine. It binds copper to form GHK-Cu. Your body makes it: it is found in blood plasma, saliva and urine, and its levels fall with age, which is where the anti-aging story starts.
In lab and animal studies, GHK-Cu prompts skin cells to make more collagen and other building blocks of the skin, and animal wounds heal faster. Whether that translates into younger-looking skin in people has not been shown.
In rats with implanted wound chambers, GHK-Cu increased collagen and other repair tissue, more at higher concentrations. In a 2023 study of skin cells and skin samples, combined with hyaluronic acid, it raised one type of collagen about twenty-five-fold in cells, but only about two-fold in the skin samples. And in a 2013 rat study of irradiated skin, it made no significant difference.
The clearest controlled human test we found in PubMed is a 2006 trial in thirteen people after laser skin resurfacing. Blinded evaluators and computer analysis found no difference in redness, wrinkles or skin quality between regimens with and without GHK-Cu. Only patient satisfaction was higher. A 2026 review called GHK-Cu promising but unproven.
A cream and an injection are different questions. In creams, GHK-Cu is a cosmetic ingredient, and claims like reverses aging are marketing, not an approved effect. The outer layer of skin also limits how much gets in. For injected GHK-Cu, there are no published human studies at all, and the FDA flags a possible risk of immune reactions.
GHK-Cu is not an FDA-approved drug. The FDA lets pharmacies compound it for routes other than injection while it reviews it, and plans to consult its advisory committee before the end of February 2027. For injectable GHK-Cu, it notes limited human safety data. In sport, it is likely covered by the anti-doping ban on unapproved substances.
Does GHK-Cu reverse skin aging? PepsRadar's claim check says unproven: the lab data are consistent, but the one randomized trial was negative on objective measures. Do cream results apply to injections? No: the route, exposure and question are different. And is it safe because the body makes it? No: natural levels say nothing about an injected product.
The bottom line: GHK-Cu is promising in lab and animal studies, its one small human trial showed no objective benefit, and a cream and an injection are different questions. For every study and source, see the GHK-Cu profile on PepsRadar dot com.
Biological role or research focus
Copper-peptide research in tissue remodeling.
Topical products, injected preparations, and animal studies answer different questions.
Role reference: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Names you may encounter
GHK Cu · GHKCU · copper peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Copper tripeptide complex
- Main research area
- Skin and tissue-remodeling research
- Evidence featured
- Small human randomized trial (topical)
- Source check
- October 4, 2026
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Quick answers
- Is GHK-Cu FDA approved?
- No. No FDA-approved drug contains GHK-Cu. FDA lists it in 503A category 1: pharmacies may compound it while FDA evaluates it. Source ↗
- Is GHK-Cu safe?
- GHK-Cu is a copper peptide used in skin products. Small skin studies exist, but FDA flagged injectable GHK-Cu for immune-reaction and impurity risks, with limited human data. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is GHK-Cu banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over GHK-Cu?
- Yes. Our records list 2 FDA actions naming it, most recently on April 15, 2026: FDA listed GHK-Cu among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Laser-resurfacing skin study (2006) | Small human randomized trial (topical) | 13 adults who completed the study after CO2 laser resurfacing around the mouth. |
| Irradiated wound model (2013) | Animal / laboratory study | Rats with surgically created skin flaps after irradiation. |
| Connective-tissue accumulation in wound chambers (1993) | Animal study | Rats with implanted wound chambers. |
Claim check
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Small human randomized trial (topical) · 2006
Laser-resurfacing skin study
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
- Population / model
- 13 adults who completed the study after CO2 laser resurfacing around the mouth.
- Study design
- Randomized to an aftercare skin regimen with or without GHK-Cu products; blinded evaluators and computer analysis over 12 weeks.
- Main finding
- No significant difference in redness resolution, wrinkles or overall skin quality on objective measures; patients using GHK-Cu reported higher satisfaction on a questionnaire.
- Limits & context
- Thirteen people, a cosmetic skin product and a mostly negative objective result. It says nothing about injected GHK-Cu, which is what FDA flagged.
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Animal / laboratory study · 2013
Irradiated wound model
Effects of topical copper tripeptide complex on wound healing in an irradiated rat model.
- Population / model
- Rats with surgically created skin flaps after irradiation.
- Study design
- Topical GHK-Cu gel versus control ointment for ten days.
- Main finding
- No significant difference was found in flap ischemia, blood-vessel measurements, or VEGF expression under the study’s analysis criteria.
- Limits & context
- This negative result belongs beside positive mechanistic claims. It does not settle all cosmetic questions, but it shows that a repair hypothesis may fail in a specific model.
Source: Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. ↗
Animal study · 1993
Connective-tissue accumulation in wound chambers
Which wound-tissue measures changed with the copper-peptide complex?
- Population / model
- Rats with implanted wound chambers.
- Study design
- Local GHK-Cu exposure compared with saline and a control tripeptide; wound contents and selected gene transcripts measured.
- Main finding
- The investigators found concentration-dependent increases in collagen, total protein, DNA, and glycosaminoglycan accumulation. Type I and III collagen messenger RNA increased; TGF-beta messenger RNA did not.
- How to read it
- The findings concern formation and accumulation of extracellular matrix in an experimental wound environment.
- Limits & context
- This is not a human wrinkle, hair-growth, or longevity trial. A local wound-chamber exposure cannot establish the performance of a cosmetic product or an injectable research preparation.
Source: Maquart et al. · Journal of Clinical Investigation · 1993 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
1 registered study names GHK-Cu as an intervention; 0 are recruiting or under way, 1 has not started recruiting yet and 0 completed. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults NCT07706361 · LifeWave, Inc. | Not yet recruiting | Not applicable | 2027-01 | 100 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
GHK-Cu is a copper peptide used in skin products. Small skin studies exist, but FDA flagged injectable GHK-Cu for immune-reaction and impurity risks, with limited human data.
Human evidence is limited to small cosmetic and post-laser skin studies that focused on appearance rather than detailed safety. No published human studies establish the safety of injected GHK-Cu.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: injectable GHK-Cu may cause immune reactions (immunogenicity) from aggregation and peptide impurities
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Topical copper tripeptide on laser-resurfaced skin (2006) ↗ · Topical copper tripeptide in an irradiated rat wound model (2013) ↗
Safety evidence & remaining uncertainty
FDA flags limited injectable safety evidence. Topical experience does not answer the risks of injecting a copper-peptide preparation.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 1 (can be compounded while FDA reviews it)
"GHK-Cu (except for injectable routes of administration)" is in 503A category 1. It was removed on April 22, 2026 after nominations were withdrawn, then restored in the May 14, 2026 update after a nominator clarified it withdrew only the injectable route. Injectable GHK-Cu was in category 2 and is now on FDA's "nominated but withdrawn" table. FDA says it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Topical cosmetic use may be viewed differently; S0 is aimed at pharmacological use. source
FDA actions
- FDA listed GHK-Cu among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Any committee vote is advisory. (2026-04-15) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHK-Cu among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
This profile includes a topical wound experiment with a negative result. Cosmetic appearance, wound closure, and systemic repair are different outcomes and cannot stand in for one another.
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Research examines copper-peptide effects on repair-associated cells and vascular signaling. Those hypotheses must be tested in the relevant tissue, formulation, and clinical problem.
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Topical products, injected preparations, and animal studies answer different questions.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does a skin-care ingredient establish an injectable therapy?
No. Route, exposure, and intended outcome differ.
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Why include a negative animal study?
It tests the proposed benefit and helps prevent a page from presenting only favorable findings.
Source: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
What does the Connective-tissue accumulation in wound chambers study show, and what does it not?
The findings concern formation and accumulation of extracellular matrix in an experimental wound environment. This is not a human wrinkle, hair-growth, or longevity trial. A local wound-chamber exposure cannot establish the performance of a cosmetic product or an injectable research preparation.
Source: Maquart et al. · Journal of Clinical Investigation · 1993 ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Animal wound study · PMID 23744835 ↗
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
- Maquart et al. · Journal of Clinical Investigation · 1993 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
How to tell if your peptides are real: check the COA with the lab
You can’t see purity in a vial, but you can check whether the testing lab really issued the certificate you were shown. Here is how, and what our own checks turned up.
Read the guide →RESEARCH FIELD GUIDE
How to read a peptide COA (certificate of analysis) without mistaking it for a guarantee
A worked example separates directory references, certificate IDs, batch numbers, reported results, and unanswered questions.
Read the guide →RESEARCH FIELD GUIDE
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
Read the guide →


